Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. - Livingston,P.O.; Adluri,S.; Helling,F.; Yao,T.J.; Kensil,C.R.; Newman,M.J.; Marciani,D. (Vaccine, 1994)